Patient 2
Younger adult women like this patient may be able to benefit from receiving Optune Gio in addition to adjuvant TMZ1
Patient 2
58, female
MGMT-unmethylated
- Married, 3 children
- Accountant at a car dealership
- Caregiver for her sister
Real patient profile provided by Kellie Kopp, RN, BSN, OCN.
Continued treatment with Optune Gio
TTFields: Optune Gio + adjuvant chemotherapy
Treatment with TTFields was started concurrently with temozolomide for 12 months
- Concurrent temozolomide with Optune Gio for 12 months
- Subsequent biopsy with LITT was performed; pathology report noted reactive changes and no tumor
Chemotherapy:
Monthly temozolomide for 11 months*
- 3 months of 200 mg/m2
- 8 months of 75 mg/m2
- 6 weeks on, 2 weeks off for 4 cycles
*Prior to LITT, patient received a total of 11 months of TMZ, including standard dosing, followed by a lower dose of TMZ.
Side effect management
Chemoradiation therapy
Effects: Fatigue, decreased appetite, constipation
Management: Laxative and stool softener plus referral to a dietitian
Optune Gio
Effects: One incident of superficial skin redness without any open areas of drainage
Management: Patient was counseled on scalp care. Good scalp hygiene was reinforced. Patient was encouraged to take short breaks from treatment
Case information used with permission from Kellie Kopp, RN, BSN, OCN.
Patient’s MRI
Case information used with permission from Kellie Kopp, RN, BSN, OCN.
Patient’s usage report
Case information used with permission from Kellie Kopp, RN, BSN, OCN.
MGMT, O-6-methylguanine-DNA methyltransferase; IDH, isocitrate dehydrogenase; ED, emergency department; WHO, World Health Organization; MRI, magnetic resonance imaging.
Reference: 1. Novocure Data on File OPT-05289.